Nomination Committee appointed in respect of AGM 2027 in Alligator Bioscience AB
Lund, Sweden, November 3, 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the Nomination Committee in prep ...
Alligator Bioscience signs agreement to sell mitazalimab to Biossil
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company whose principal asset is a financial interest i ...
Change in number of shares and votes in Alligator Bioscience AB
During October 2026, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a resul ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
The Board of Directors of Alligator Bioscience proposes a reverse share split of ordinary shares
The Board of Directors of Alligator Bioscience AB (“Alligator Bioscience” or the ”Company”) proposes that an Extraor ...
Alligator Bioscience AB reports financial results for the period 1 January – 30 September 2026 and provides a business update
Rights issue completed: The rights issue was subscribed to approximately 17.1 percent, and guarantee commitments covered a further 29.7 perc ...
Invitation to Alligator Bioscience’s interim report call on 22 October 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company whose principal asset is a financial interest i ...
Alligator Bioscience appoints Johan Giléus as CEO – Søren Bregenholt to step down at year-end
Johan Giléus, currently CFO, has been appointed CEO effective 1 January 2027 Søren Bregenholt will remain CEO until 31 Decembe ...
Alligator Bioscience carries out a directed issue of warrants to Fenja Capital in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...